Oramed Pharmaceuticals (NASDAQ:ORMP) Trading 11.4% Higher

Shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) were up 11.4% during mid-day trading on Monday . The stock traded as high as $5.22 and last traded at $5.10, approximately 327,976 shares changed hands during mid-day trading. An increase of 289% from the average daily volume of 84,346 shares. The stock had previously closed at $4.58.

Several analysts have commented on the company. HC Wainwright set a $20.00 price objective on Oramed Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, September 18th. ValuEngine downgraded Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 29th. Finally, LADENBURG THALM/SH SH assumed coverage on Oramed Pharmaceuticals in a report on Wednesday, September 11th. They issued a “buy” rating and a $7.00 target price on the stock.

The business’s 50-day moving average is $3.26 and its two-hundred day moving average is $3.29. The stock has a market capitalization of $79.69 million, a PE ratio of 6.22 and a beta of 1.41.

Institutional investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new position in Oramed Pharmaceuticals during the 3rd quarter worth $50,000. Tower Research Capital LLC TRC lifted its stake in shares of Oramed Pharmaceuticals by 1,137.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 18,491 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 16,997 shares during the period. Jane Street Group LLC purchased a new stake in shares of Oramed Pharmaceuticals in the second quarter valued at about $155,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Oramed Pharmaceuticals by 50.5% in the second quarter. Renaissance Technologies LLC now owns 158,098 shares of the biotechnology company’s stock valued at $568,000 after acquiring an additional 53,043 shares in the last quarter. Institutional investors own 4.37% of the company’s stock.

Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

Further Reading: How to Invest in Stocks with Increasing Dividends

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.